Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze

Behavioural Brain Research

Volumn 176, Issue 2, 2007, Pages 202-209

  Drapier, Dominique ^a   Bentué Ferrer, Danièle ^b,c   Laviolle, Bruno ^d   Millet, Bruno ^a   Allain, Hervé ^b,c   Bourin, Michel ^c   Reymann, Jean Michel ^b,c  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b Inst de Rech Contre le Cancer IRCC   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Antidepressants; Anxiety; Ethological parameters; Plus maze; Rats

Indexed keywords

DESIPRAMINE; DIAZEPAM; FLUOXETINE; PAROXETINE;

ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLUOXETINE; MALE; MAZE LEARNING; PAROXETINE; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS;

EID: 33845305830     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2006.10.002     Document Type: Article

References (47)

1. Argyropoulos S.V., Sandford J.J., and Nutt D.J. The psychobiology of anxiolytic drugs. Part 2. Pharmacological treatments of anxiety. Pharmacol Ther 88 (2000) 213-227
2. Bagdy G., Graf M., Anheuer Z.E., Modos E.A., and Kantor S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 4 (2001) 399-408
3. Ball S.G., Kuhn A., Wall D., Shekhar A., and Goddard A.W. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 66 (2005) 94-99
4. Belzung C. Rodent models of anxiety-like behaviors: are they predictive for compounds acting via non-benzodiazepine mechanisms?. Curr Opin Invest Drugs 2 (2001) 1108-1111
5. Carobrez A.P., and Bertoglio L.J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci Biobehav Rev 29 (2005) 1193-1205
6. Berlant J. New drug development for post-traumatic stress disorder. Curr Opin Invest Drugs 4 (2003) 37-41
7. Blanco C., Raza M.S., Schneier F.R., and Liebowitz M.R. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol 6 (2003) 427-442
8. Boothman L.J., Mitchell S.N., and Sharp T. Investigation of the SSRI augmentation properties of 5-HT(2) receptor antagonists using in vivo microdialysis. Neuropharmacology 50 (2006) 726-732
9. Borelli K.G., Nobre M.J., Brandao M.L., and Coimbra N.C. Effects of acute and chronic fluoxetine and diazepam on freezing behavior induced by electrical stimulation of dorsolateral and lateral columns of the periaqueductal gray matter. Pharmacol Biochem Behav 77 (2004) 557-566
10. Borsini F., Podhorna J., and Marazziti D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants?. Psychopharmacology (Berlin) 163 (2002) 121-141
11. Bourin M., Chue P., and Guillon Y. Paroxetine: a review. CNS Drug Rev 7 (2001) 25-47
12. Briley M., Chopin P., and Moret C. Effect of serotonergic lesion on "anxious" behaviour measured in the elevated plus-maze test in the rat. Psychopharmacology (Berlin) 101 (1990) 187-189
13. Bruce S.E., Vasile R.G., Goisman R.M., Salzman C., Spencer M., Machan J.T., et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia?. Am J Psychiatry 160 (2003) 1432-1438
14. David D.J., Bourin M., Jego G., Przybylski C., Jolliet P., and Gardier A.M. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br J Pharmacol 140 (2003) 1128-1136
15. Donnelly C.L. Pharmacologic treatment approaches for children and adolescents with posttraumatic stress disorder. Child Adolesc Psychiatr Clin N Am 12 (2003) 251-269
16. Felton T.M., Kang T.B., Hjorth S., and Auerbach S.B. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 367 (2003) 297-305
17. Gordon J.A., and Hen R. The serotonergic system and anxiety. Neuromol Med 5 (2004) 27-40
18. Greist J.H., Bandelow B., Hollander E., Marazziti D., Montgomery S.A., Nutt D.J., et al. World Council of Anxiety. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectrosc 8 8 Suppl 1 (2003) 7-16
19. Griebel G. 5-Hydroxytryptamine interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65 (1995) 319-395
20. Griebel G., Cohen C., Perrault G., and Sanger D.J. Behavioral effects of acute and chronic fluoxetine in Wistar-Kyoto rats. Physiol Behav 67 (1999) 315-320
21. Griebel G., Rodgers R.J., Perrault G., and Sanger D.J. Risk assessment behavior: evaluation of utility in the study of 5-HT related drugs in the rat elevated plus-maze test. Pharmacol Biochem Behav 57 (1997) 817-827
22. Handley S. Serotonin in animal model of anxiety: the importance of stimulus and response. In: Cowen P., and Idzikowski C. (Eds). Serotonin, sleep and mental disorder (1991), Wrighston, Petersfield 89-115
23. Handley S., and McBlane J.W. 5-HT drugs in animal models of anxiety. Psychopharmacology (Berlin) 112 (1993) 13-20
24. Handley S.L., Mc Blane J.W., Critchley M.A., and Njung'e K. Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors. Behav Brain Res 58 (1993) 203-210
25. Holmes A., and Rodgers R.J. Prior exposure to the elevated plus-maze sensitizes mice to the acute behavioral effects of fluoxetine and phenelzine. Eur J Pharmacol 459 (2003) 221-230
26. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SRRIs). Int Clin Psychopharmacol 9 Suppl 1 (1994) 19-26
27. Janowsky D.S., and Byerley B. Desipramine: an overview. J Clin Psychiatry 45 (1984) 3-9
28. Kapczinski F., Lima M.S., Souza J.S., and Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2 (2003) CD003592
29. Koks S., Beljajev S., Koovit I., Abramov U., Bourin M., and Vasar E. 8-OH-DPAT, but not deramiclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology (Berlin) 153 (2001) 365-372
30. Kurt M., Arik A.C., and Celik S. The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice. J Basic Physiol Pharmacol 11 (2000) 173-180
31. Lin D., and Parsons L.H. Anxiogenic-like effect of serotonin (1B) receptor stimulation in the rat elevated plus-maze. Pharmacol Biochem Behav 71 (2002) 581-587
32. Lister R. Ethologically-based animal models of anxiety disorders. Pharmacol Ther 46 (1990) 321-340
33. Millan M.J. The neurobiology and control of anxious states. Prog Neurobiol 70 (2003) 83-244
34. Millan M.J. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 60 (2005) 441-460
35. Nash L.T., and Hack S. The pharmacological treatment of anxiety disorders in children and adolescents. Expert Opin Pharmacother 3 (2002) 555-571
36. Pellow S., Chopin P., File S.E., and Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Meth 14 (1985) 149-167
37. Rodrigues-Filho R., and Takahashi R.N. Antinociceptive effects induced by desipramine and fluoxetine are dissociated from their antidepressant or anxiolytic action in mice. Int J Neuropsychopharmacol 2 (1999) 263-269
38. Rossi A., Barraco A., and Donda P. Fluoxetine: a review on evidence based medicine. Ann Gen Hosp Psychiatry 3 (2004) 2
39. Roy V., and Chapillon P. Further evidences that risk assessment and object exploration behaviours are useful to evaluate emotional reactivity in rodents. Behav Brain Res 154 (2004) 439-448
40. Salchner P., and Singewald N. Neuroanatomical substrates involved in the anxiogenic-like effect of acute fluoxetine treatment. Neuropharmacology 43 (2002) 1238-1248
41. Silva M.T., Alves C.R., and Santarem E.M. Anxiogenic-like effect of acute and chronic fluoxetine on rats tested on the elevated plus-maze. Braz J Med Biol Res 32 (1999) 333-339
42. Silva R.C., and Brandao M.L. Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: an ethological analysis. Pharmacol Biochem Behav 65 (2000) 209-216
43. Sramek J.J., Zarotsky V., and Cutler N.R. Generalised anxiety disorder: treatment options. Drugs 62 (2002) 1635-1648
44. Stahl S.M. Basic psychopharmacology of antidepressants. Part 1. Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 59 Suppl 4 (1998) 5-14
45. Stewart S.H., and Westra H.A. Benzodiazepine side-effects: from the bench to the clinic. Curr Pharm Des 8 (2002) 1-3
46. Troelsen K.B., Nielsen E.O., and Mirza N.R. Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology (Berlin) 181 (2005) 741-750
47. Varty G.B., Morgan C.A., Cohen-Williams M.E., Coffin V.L., and Carey G.J. The gerbil elevated plus-maze. I. Behavioral characterization and pharmacological validation. Neuropsychopharmacology 27 (2002) 357-370